Company intelligence / Profile preview

TechnoGenesys

St. Louis, Missouri, USAventureradar.com ↗

Ownership: Private
Development stage: Other

Overview

TechnoGenesys is developing a first-in-class dual-action small molecule inhibitor, Mahatinib ((R)-9b), which targets both ACK1 kinase and the androgen receptor. The compound has shown promise in overcoming resistance to current therapies for prostate cancer and demonstrates immune-regulatory activity. A first-in-human Phase I clinical trial ("PHAROS") will begin in early/mid 2025 with initial proof-of-concept data expected by Q3 2025. The company also plans to develop companion diagnostics for personalized medicine approaches

Therapeutic areas: Oncology
Modalities: Small moleculeKinase inhibitorAndrogen receptor antagonist
Industry: Biotech

Drug pipeline

1 asset

mahatinib

Partnerships

No major pharma or biotech partnerships disclosed as of June 2025; NIH/NCI grant funding received for clinical trialsOpen to VC/pharma investment partners for future rounds

Beyond the preview

Go deeper on TechnoGenesys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TechnoGenesys.

Explore the full profile